Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease

被引:2
|
作者
Wawruch, Martin [1 ]
Murin, Jan [2 ]
Tesar, Tomas [3 ]
Paduchova, Martina [4 ]
Petrova, Miriam [1 ]
Celovska, Denisa [2 ]
Havelkova, Beata [5 ]
Trnka, Michal [6 ]
Aarnio, Emma [7 ,8 ]
机构
[1] Comenius Univ, Fac Med, Inst Pharmacol & Clin Pharmacol, Bratislava 81108, Slovakia
[2] Comenius Univ, Fac Med, Dept Internal Med 1, Bratislava 81369, Slovakia
[3] Comenius Univ, Fac Pharm, Dept Org & Management Pharm, Bratislava 83232, Slovakia
[4] Hlth Ctr, Dept Angiol, Trnava 91701, Slovakia
[5] Gen Hlth Insurance Co, Bratislava 85104, Slovakia
[6] Comenius Univ, Fac Med, Inst Med Phys Biophys Informat & Telemed, Bratislava 81372, Slovakia
[7] Univ Turku, Inst Biomed, Turku 20014, Finland
[8] Univ Eastern Finland, Sch Pharm, Kuopio 70211, Finland
关键词
peripheral arterial disease; antiplatelet; reinitiation; discontinuation; non-persistence; diabetes mellitus; atrial fibrillation; ACUTE MYOCARDIAL-INFARCTION; MANAGEMENT; GUIDELINES; ADHERENCE; MORTALITY; STATINS; ESC;
D O I
10.3390/biomedicines9091280
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The successful treatment of peripheral arterial disease (PAD) depends on adequate adherence to medications including antiplatelet agents. The aims of this study were (a) to identify the proportion of nonpersistent patients who reinitiated antiplatelet therapy and how many of them discontinued therapy after reinitiation, and (b) to identify patient- and medication-related characteristics associated with the likelihood of reinitiation and discontinuation among reinitiators. The analysis of reinitiation was conducted on 3032 nonpersistent users of antiplatelet agents aged >= 65 years, with PAD newly diagnosed in 2012. Discontinuation (i.e., a treatment gap of >= 6 months without antiplatelet medication prescription) was analysed in 2006 reinitiating patients. To identify factors associated with the likelihood of reinitiation and discontinuation, Cox regression with time-dependent covariates was used. Reinitiation was recorded in 2006 (66.2%) of 3032 patients who had discontinued antiplatelet medication. Among these 2006 reinitiators, 1078 (53.7%) patients discontinued antiplatelet therapy again. Ischemic stroke and myocardial infarction during non-persistence and bronchial asthma/chronic obstructive pulmonary disease were associated with an increased likelihood of reinitiation. University education was associated with discontinuation among reinitiators. Factors associated with the probability of reinitiation and discontinuation in reinitiators make it possible to identify older PAD patients in whom "stop-starting" behaviour may be expected.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Factors Associated with Reinitiation of Statin Treatment in Older Patients with Peripheral Arterial Disease
    Martin Wawruch
    Gejza Wimmer
    Jan Murin
    Martina Paduchova
    Tomas Tesar
    Lubica Hlinkova
    Peter Slavkovsky
    Emma Aarnio
    [J]. Drugs & Aging, 2020, 37 : 595 - 604
  • [2] Factors Associated with Reinitiation of Statin Treatment in Older Patients with Peripheral Arterial Disease
    Wawruch, Martin
    Wimmer, Gejza, Jr.
    Murin, Jan
    Paduchova, Martina
    Tesar, Tomas
    Hlinkova, Lubica
    Slavkovsky, Peter
    Aarnio, Emma
    [J]. DRUGS & AGING, 2020, 37 (08) : 595 - 604
  • [3] Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease
    Poredos, P.
    Jezovnik, M. K.
    [J]. INTERNATIONAL ANGIOLOGY, 2010, 29 (01) : 20 - 26
  • [4] Antiplatelet therapy of patients with peripheral arterial disease
    Poredos, P.
    [J]. MULTIDISCIPLINARY APPROACH TO CARDIOVASCULAR DISEASES, 2016, : 12 - 16
  • [5] Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease
    Wawruch, Martin
    Murin, Jan
    Tesar, Tomas
    Paduchova, Martina
    Petrova, Miriam
    Celovska, Denisa
    Havelkova, Beata
    Trnka, Michal
    Aarnio, Emma
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
    Klonaris, Chris
    Patelis, Nikolaos
    Drebes, Anja
    Matheiken, Sean
    Liakakos, Theodoros
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (29) : 4610 - 4616
  • [7] A critical review of antiplatelet treatment in peripheral arterial disease
    Violi, F.
    Hiatt, W.
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2007, 2 (02) : 84 - 87
  • [8] A critical review of antiplatelet treatment in peripheral arterial disease
    F. Violi
    W. Hiatt
    [J]. Internal and Emergency Medicine, 2007, 2 : 84 - 87
  • [9] Antiplatelet therapy in patients with peripheral arterial disease (PAD)
    Diehm, C
    Lawall, H
    Huber, R
    [J]. MEDIZINISCHE KLINIK, 2004, 99 : 14 - 20
  • [10] ANTIPLATELET THERAPY IN HOSPITALIZED PATIENTS WITH ASYMPTOMATIC PERIPHERAL ARTERIAL DISEASE
    Roig-Espert, B.
    Tamarit-Garcia, J. J.
    Garcia-Tolosa, F.
    Saez-Segura, A.
    Giner-Morales, J.
    Carbonell-Casan, I.
    Sanchez-Suarez, L.
    Sala-Sainz, C.
    Navarro-Ibanez, V.
    Artero-Mora, A.
    [J]. JOURNAL OF HYPERTENSION, 2010, 28 : E554 - E554